Literature DB >> 15269214

A 10-amino acid domain within human T-cell leukemia virus type 1 and type 2 tax protein sequences is responsible for their divergent subcellular distribution.

Laurent Meertens1, Sébastien Chevalier, Robert Weil, Antoine Gessain, Renaud Mahieux.   

Abstract

Human T-cell leukemia virus type 1 and type 2 (HTLV-1/2) are related retroviruses that infect T-lymphocytes. Whereas HTLV-1 infection can cause leukemia, HTLV-2 has not been demonstrated to be the agent of a hematological malignant disease. Nevertheless, the virally encoded Tax-1 and Tax-2 transactivators display a high percentage of similarity. Tax-1 is a shuttling protein that contains a noncanonical nuclear localization signal as well as a nuclear export signal. The presence of the nuclear localization signal and the nuclear export signal domains in the Tax-2 sequence has not been determined. The distribution of Tax-2 in infected cells is not known but has been assumed to be similar to that of Tax-1. By using a Tax-2-specific antibody, we report here that Tax-2 is located predominantly in the cytoplasm of the HTLV-2 immortalized or transformed infected T-cells. These results were confirmed after transient transfection of untagged Tax-1 and Tax-2 constructs, histidine tag Tax1/Tax2, GFP-Tax, and Tax-GFP fusion constructs in several cell lines. We show that this unanticipated localization is not due to a default in the Tax-2 nuclear localization signal functions nor to major differences in Tax-2 versus Tax-1 binding to the IKKgamma/NEMO protein. In addition, we demonstrate that inhibiting the proteasome results in a relocalization of Tax-1 in the cytoplasm, similar to that of Tax-2. By using a series of Tax-1/Tax-2 chimeras, we determined that the minimal domain that is necessary for Tax-2 peculiar distribution encompasses amino acids 90-100. Finally, we show a high correlation between intracellular localization of Tax and their NF-kappaB or CREB transactivating ability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15269214     DOI: 10.1074/jbc.M400497200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

Review 1.  Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2.

Authors:  Gerold Feuer; Patrick L Green
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

2.  Human T-cell lymphotropic virus type 3: complete nucleotide sequence and characterization of the human tax3 protein.

Authors:  Sara Calattini; Sébastien Alain Chevalier; Renan Duprez; Philippe Afonso; Alain Froment; Antoine Gessain; Renaud Mahieux
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  A Transgenic Drosophila melanogaster Model To Study Human T-Lymphotropic Virus Oncoprotein Tax-1-Driven Transformation In Vivo.

Authors:  Margret Shirinian; Zakaria Kambris; Lama Hamadeh; Caroline Grabbe; Chloé Journo; Renaud Mahieux; Ali Bazarbachi
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

4.  Human T cell leukemia virus type 2 (HTLV-2) Tax2 has a dominant activity over HTLV-1 Tax1 to immortalize human CD4+ T cells.

Authors:  Michitaka Imai; Masaya Higuchi; Hiroki Kawamura; Manami Yoshita; Masahiko Takahashi; Masayasu Oie; Hideaki Matsuki; Yuetsu Tanaka; Yutaka Aoyagi; Masahiro Fujii
Journal:  Virus Genes       Date:  2012-09-29       Impact factor: 2.332

5.  Human T-cell leukemia virus type 2 antisense viral protein 2 is dispensable for in vitro immortalization but functions to repress early virus replication in vivo.

Authors:  Han Yin; Priya Kannian; Nathan Dissinger; Robyn Haines; Stefan Niewiesk; Patrick L Green
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

6.  Cooperation of NF-kappaB2/p100 activation and the PDZ domain binding motif signal in human T-cell leukemia virus type 1 (HTLV-1) Tax1 but not HTLV-2 Tax2 is crucial for interleukin-2-independent growth transformation of a T-cell line.

Authors:  Masaya Higuchi; Chikako Tsubata; Rie Kondo; Sakiko Yoshida; Masahiko Takahashi; Masayasu Oie; Yuetsu Tanaka; Renaud Mahieux; Masao Matsuoka; Masahiro Fujii
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

7.  Human T-cell leukemia virus type 1 Tax induces an aberrant clustering of the tumor suppressor Scribble through the PDZ domain-binding motif dependent and independent interaction.

Authors:  Masaaki Okajima; Masahiko Takahashi; Masaya Higuchi; Toshiaki Ohsawa; Sakiko Yoshida; Yutaka Yoshida; Masayasu Oie; Yuetsu Tanaka; Fumitake Gejyo; Masahiro Fujii
Journal:  Virus Genes       Date:  2008-07-26       Impact factor: 2.332

8.  Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classic bZIP domain but still inhibits Tax2-mediated transcription.

Authors:  Marilène Halin; Estelle Douceron; Isabelle Clerc; Chloé Journo; Nga Ling Ko; Sébastien Landry; Edward L Murphy; Antoine Gessain; Isabelle Lemasson; Jean-Michel Mesnard; Benoît Barbeau; Renaud Mahieux
Journal:  Blood       Date:  2009-07-14       Impact factor: 22.113

9.  Preexisting infection with human T-cell lymphotropic virus type 2 neither exacerbates nor attenuates simian immunodeficiency virus SIVmac251 infection in macaques.

Authors:  Shari N Gordon; Anna R Weissman; Valentina Cecchinato; Claudio Fenizia; Zhong-Min Ma; Tzong-Hae Lee; Lorenzo Zaffiri; Vibeke Andresen; Robyn Washington Parks; Kathryn S Jones; Jean Michel Heraud; Maria Grazia Ferrari; Hye Kyung Chung; David Venzon; Renaud Mahieux; Edward L Murphy; Steven Jacobson; Christopher J Miller; Francis W Ruscetti; Genoveffa Franchini
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

10.  NRP/Optineurin Cooperates with TAX1BP1 to potentiate the activation of NF-kappaB by human T-lymphotropic virus type 1 tax protein.

Authors:  Chloé Journo; Josina Filipe; Frédégonde About; Sébastien A Chevalier; Philippe V Afonso; John N Brady; David Flynn; Frédéric Tangy; Alain Israël; Pierre-Olivier Vidalain; Renaud Mahieux; Robert Weil
Journal:  PLoS Pathog       Date:  2009-07-17       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.